Sana Biotechnology, Inc.
US ˙ NasdaqGS ˙ US7995661045

Introduction

This page provides a comprehensive analysis of the known insider trading history of Steve Harr. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Steve Harr has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SANA / Sana Biotechnology, Inc. President & CEO, Director 7,876,930
US:LOXO / Loxo Oncology, Inc. Director 0
US:JUNO / Juno Therapeutics, Inc. CFO & Head, Corp. Development 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Steve Harr. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SANA / Sana Biotechnology, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SANA / Sana Biotechnology, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SANA / Sana Biotechnology, Inc. Insider Trades
Insider Sales SANA / Sana Biotechnology, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SANA / Sana Biotechnology, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SANA / Sana Biotechnology, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Steve Harr as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-10 2025-03-10 4 SANA Sana Biotechnology, Inc.
Common Stock
F - Taxes -12,820 7,876,930 -0.16 2.56 -32,819 20,164,941
2025-03-10 2025-03-07 4 SANA Sana Biotechnology, Inc.
Common Stock
M - Exercise 50,000 7,889,750 0.64
2022-04-15 2021-04-14 4 SANA Sana Biotechnology, Inc.
Common Stock
G - Gift -167,000 7,839,750 -2.09
2022-04-15 2021-04-14 4 SANA Sana Biotechnology, Inc.
Common Stock
G - Gift -167,000 7,839,750 -2.09
2022-03-08 2022-03-03 4 SANA Sana Biotechnology, Inc.
Stock Options (Right to Buy)
A - Award 760,000 760,000
2021-02-10 2021-02-08 4 SANA Sana Biotechnology, Inc.
Series B Convertible Preferred Stock
C - Conversion -156,250 0 -100.00
2021-02-10 2021-02-08 4 SANA Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -800,000 0 -100.00
2021-02-10 2021-02-08 4 SANA Sana Biotechnology, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -1,075,000 0 -100.00
2021-02-10 2021-02-08 4 SANA Sana Biotechnology, Inc.
Common Stock
C - Conversion 2,031,250 8,173,750 33.07
2021-02-03 3 SANA Sana Biotechnology, Inc.
Common Stock
6,142,500
2021-02-03 3 SANA Sana Biotechnology, Inc.
Common Stock
682,500
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -8,750 0 -100.00 235.00 -2,056,250
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -11,000 0 -100.00 235.00 -2,585,000
2019-02-15 2019-02-15 4 LOXO Loxo Oncology, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -15,625 0 -100.00 235.00 -3,671,875
2018-06-14 2018-06-13 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 8,750 8,750
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -127,841 0 -100.00
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -155,000 0 -100.00
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -85,000 0 -100.00
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -98,750 0 -100.00
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
D - Sale to Issuer -35,893 0 -100.00
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
D - Sale to Issuer -11,544 35,893 -24.34
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
D - Sale to Issuer -29,135 47,437 -38.05
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
D - Sale to Issuer -20,580 76,572 -21.18
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
D - Sale to Issuer -50,010 97,152 -33.98 87.00 -4,350,870 8,452,224
2018-03-07 2018-03-05 4 JUNO Juno Therapeutics, Inc.
Common Stock
U - Other -492,355 147,162 -76.99 87.00 -42,834,885 12,803,094
2018-03-01 2018-02-27 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 11,544 639,517 1.84
2018-02-09 2018-02-07 4 JUNO Juno Therapeutics, Inc.
Common Stock
G - Gift -162,790 627,973 -20.59
2018-02-09 2018-02-07 4 JUNO Juno Therapeutics, Inc.
Common Stock
F - Taxes -1,704 790,763 -0.22 85.49 -145,675 67,602,329
2018-02-02 2018-01-31 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 29,135 792,467 3.82
2017-12-22 2017-12-21 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -8,750 98,750 -8.14
2017-12-22 2017-12-21 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale X -500 763,332 -0.07 45.18 -22,591 34,488,866
2017-12-22 2017-12-21 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale X -8,250 763,832 -1.07 44.74 -369,083 34,171,781
2017-12-22 2017-12-21 4 JUNO Juno Therapeutics, Inc.
Common Stock
M - Exercise 8,750 772,082 1.15 8.72 76,300 6,732,555
2017-10-20 2017-10-20 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 35,893 763,332 4.93
2017-07-05 2017-07-03 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -8,750 107,500 -7.53
2017-07-05 2017-07-03 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -8,750 727,439 -1.19 30.00 -262,500 21,823,170
2017-07-05 2017-07-03 4 JUNO Juno Therapeutics, Inc.
Common Stock
M - Exercise 8,750 736,189 1.20 8.72 76,300 6,419,568
2017-06-29 2017-06-27 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -8,750 116,250 -7.00
2017-06-29 2017-06-27 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -8,750 727,439 -1.19 30.00 -262,501 21,823,243
2017-06-29 2017-06-27 4 JUNO Juno Therapeutics, Inc.
Common Stock
M - Exercise 8,750 736,189 1.20 8.72 76,300 6,419,568
2017-06-23 2017-06-22 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 11,000 11,000
2017-02-09 2017-02-07 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 127,841 127,841
2017-02-09 2017-02-07 4 JUNO Juno Therapeutics, Inc.
Common Stock
A - Award 27,439 727,439 3.92
2016-11-09 2016-11-07 4 LOXO Loxo Oncology, Inc.
Director Stock Option (right to buy)
A - Award 15,625 15,625
2016-06-13 2016-06-10 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -16,052 700,000 -2.24 43.69 -701,370 30,585,520
2016-06-13 2016-06-10 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -13,948 716,052 -1.91 42.88 -598,160 30,707,890
2016-03-04 2016-03-04 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -5,000 730,000 -0.68 45.00 -225,000 32,850,000
2016-03-02 2016-03-01 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -43 735,000 -0.01 39.88 -1,715 29,311,800
2016-03-02 2016-03-01 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -10,076 735,043 -1.35 39.21 -395,061 28,819,639
2016-03-02 2016-03-01 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -6,387 745,119 -0.85 38.18 -243,863 28,449,538
2016-03-02 2016-03-01 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -900 751,506 -0.12 36.82 -33,134 27,667,144
2016-03-02 2016-03-01 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -10,581 752,406 -1.39 36.20 -382,997 27,234,614
2016-03-02 2016-03-01 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -2,013 762,987 -0.26 35.06 -70,571 26,748,646
2016-02-04 2016-02-02 4 JUNO Juno Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 155,000 155,000
2015-12-11 2015-12-10 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -3,600 765,000 -0.47 46.90 -168,824 35,875,058
2015-12-11 2015-12-10 4 JUNO Juno Therapeutics, Inc.
Common Stock
S - Sale -31,400 768,600 -3.92 46.38 -1,456,250 35,645,670
2015-03-26 2015-03-03 4/A JUNO Juno Therapeutics, Inc.
Stock Option (right to buy)
A - Award 85,000 85,000
2015-03-05 2015-03-03 4 JUNO Juno Therapeutics, Inc.
Stock Option (right to buy)
A - Award 70,000 70,000
2014-12-18 3 JUNO Juno Therapeutics, Inc.
Common Stock
1,600,000
2014-12-18 3 JUNO Juno Therapeutics, Inc.
Common Stock
1,600,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)